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Abstract
Objective—To update the projected prevalence of arthritis and arthritis-attributable activity 
limitations among US adults, using a newer baseline for estimates.
Methods—Baseline prevalence data were obtained from the 2010–2012 National Health 
Interview Survey. Arthritis was defined as an answer of “yes” to the question “Have you ever been 
told by a doctor or other health professional that you have some form of arthritis, rheumatoid 
arthritis, gout, lupus or fibromyalgia?” Arthritis-attributable activity limitation was defined as an 
answer of “yes” to the question “Are you limited in any way in any of your usual activities 
because of arthritis or joint symptoms?” The baseline prevalence of arthritis and arthritis-
attributable activity limitation was stratified according to age and sex and was statistically 
weighted to account for the complex survey design. The projected prevalence of doctor-diagnosed 
arthritis and arthritis-attributable activity limitation was calculated by multiplying the age- and 
sex-stratified population estimates projected for 2015–2040 (in 5-year intervals; provided by the 
US Census Bureau) by the baseline estimates. Age-and sex-specific prevalences were summed to 
provide the total prevalence estimates for each year.
Results—In 2010–2012, 52.5 million adults in the US (22.7% of all adults) had doctor-diagnosed 
arthritis, and 22.7 million (9.8%) had arthritis-attributable activity limitation. By 2040, the number 
of US adults with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million (25.9% of 
all adults), and the number of adults with arthritis-attributable activity limitation will increase 52% 
to 34.6 million (11.4% of all adults).
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Conclusion—Updated projections suggest that arthritis and arthritis-attributable activity 
limitation will remain large and growing problems for clinical and public health systems, which 
must plan and create policies and resources to address these future needs.
Arthritis and other rheumatic conditions affect 53 million US adults ages 18 and older (1), 
are the most common cause of disability (2), and are associated with considerable pain, 
activity limitation, and restriction of work and social participation (1,3–5). Projecting 
changes in the prevalence and impact of chronic diseases such as arthritis is crucial for 
planning future clinical and public health needs, informing health policy, and establishing 
priorities for planning and resource allocation.
The aging of the population is a factor that has driven previous projections of arthritis 
prevalence and the associated impact (6). A new report from the US Census Bureau 
confirms that aging will remain an important factor in the future: by the time of the 2030 
census, all “baby boomers” will have reached age 65 years, and 1 in 5 US adults will be 65 
years of age or older (7).
Previous projections of arthritis prevalence (6) based on 2003 data have tracked well against 
subsequent arthritis prevalence estimates (1). For example, the prevalence of arthritis was 
52.5 million in 2010–2012 (1), and in 2003 the prevalence projected for 2015 was 55.7 
million (6), which is consistent with the observed net increase in prevalence of ~1 million 
per year. In contrast, the prevalence of arthritis-attributable activity limitation for 2010–2012 
(22.7 million) (1) has already surpassed the prevalence projected for 2020 (22.1 million) (6), 
which is higher than the previously observed net increase of ~500,000 per year. Given the 
apparent change in the prevalence of arthritis-attributable activity limitation, the purpose of 
this study was to update the age- and sex-specific projections for arthritis prevalence and 
arthritis-attributable activity limitation in adults ages 18 years and older through 2040, using 
a newer baseline for estimates.
PATIENTS AND METHODS
The National Health Interview Survey (NHIS), which is one of the major data collection 
programs of the National Center for Health Statistics (NCHS), is an annual population-based 
survey that uses a complex stratified sample design to collect data on ~30,000 households 
(children and adults). The Sample Adult Core contains detailed health information on 1 
adult who was randomly selected from each sampled household; these adults completed a 
questionnaire administered in-person by a trained interviewer. The NHIS provides national 
estimates for the non-institutionalized civilian US population (8).
In contrast to the prior projection using a single year of data (2003) for baseline estimates 
(6), this analysis used a 3- year (2010–2012) rolling average for 2 reasons: 1) a rolling 
average will likely smooth any year-to-year random variation in baseline estimates, and 2) 
these years are the basis for current estimates of the prevalence of arthritis and arthritis-
attributable activity limitation (1). The unweighted sample size and response rates for the 
Sample Adult Core were 27,157 (60.8%), 33,014 (66.3%), and 34,525 (61.2%) for 2010, 
2011, and 2012, respectively. A case of doctor-diagnosed arthritis was defined as an answer 
of “yes” to the question “Have you ever been told by a doctor or other health professional 
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that you have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia?” This 
definition of arthritis has been cognitively tested and validated for population surveillance 
purposes (9). Among adults with doctor-diagnosed arthritis, arthritis-attributable activity 
limitation was defined as an answer of “yes” to the question “Are you limited in any way in 
any of your usual activities because of arthritis or joint symptoms?”
The baseline prevalence of doctor-diagnosed arthritis and arthritis-attributable activity 
limitation according to age and sex was estimated using sample weights provided by the 
NCHS to account for the complex survey design. Projected estimates of the population of 
persons ages 18 years and older, according to age and sex, for 2015–2040 were obtained 
from the US Census Bureau (10). These projected population estimates are based on the July 
1, 2013 population estimates, which in turn use the 2010 census as the base.
The projected prevalence of doctor-diagnosed arthritis and arthritis-attributable activity 
limitation, overall and stratified by age and sex, was calculated by multiplying the projected 
estimate of the population (in 5-year intervals) by the baseline 3-year rate provided by the 
NHIS. We analyzed age in predefined strata combinations to determine the narrowest age 
bands across all age and sex groups that consistently met NCHS standards for reliability 
(ages 18–34, 35–44, 45–54, 55–64, 65–74, 75–84, and 85+ years). Age- and sex-specific 
prevalences were summed to provide the total prevalence of doctor-diagnosed arthritis and 
arthritis-attributable activity limitation for each year.
RESULTS
In 2010–2012, 52.5 million US adults (22.7% of all adults) had doctor-diagnosed arthritis, 
and 22.7 million had arthritis-attributable activity limitation (Table 1). By 2040, the 
prevalence of doctor-diagnosed arthritis is projected to increase 49% to 78.4 million (25.9% 
of the adult population) (Table 2), and the prevalence of arthritis-attributable activity 
limitation will increase 52% to 34.6 million (11.4% of the population [43.2% of adults with 
arthritis]) (Table 2). In 2040, women will continue to account for the majority of arthritis 
cases (58.5%; 45.8 million).
Between 2015 and 2040, the number of adults with doctor-diagnosed arthritis will increase 
37% among men and 34% among women, while the number with arthritis-attributable 
activity limitation will increase 40% among men and 36% among women. For both men and 
women, the largest increase (from 73% to 78%) in the prevalence of doctor-diagnosed 
arthritis and arthritis-attributable activity limitation will occur in the group of adults ages 65 
years and older (data not shown). Adults in the traditional working-age population (ages 18–
64 years) currently comprise the majority of affected adults. Adults in this age group will 
continue to comprise the majority of affected adults through 2025 and fully 47–48% of 
affected adults through 2040 (Figure 1), when 36.9 million will be affected. Given 
increasing trends in the upper age limit of what is classified as “working age” (11), those in 
an expanded working-age population may continue to comprise the majority of affected 
adults through 2040.
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DISCUSSION
These projections based on the current age- and sex-specific prevalence suggest that by 
2040, 1 in 4 US adults (78.4 million) will have doctor-diagnosed arthritis, and 1 in 9 adults 
(34.6 million) will have arthritis-attributable activity limitation. Given that previous 
projections for the prevalence of arthritis-attributable activity limitation underestimated the 
observed prevalence for reasons that are not yet clear, the latter projection may also be low. 
Projected increases are similar in both sexes.
Not surprisingly, the largest population growth is among adults ages 65 years and older, 
because as baby boomers age, they become part of a higher-risk age group. This will likely 
have serious effects on Social Security Disability Income (SSDI) and Medicare programs. 
Between 1981 and 2000, SSDI benefits for musculoskeletal conditions increased 41%, 
surpassing circulatory disorders as the condition most frequently associated with the receipt 
of benefits (12). The SSDI trust fund is expected to be exhausted in 2016 (13). Between 
1987 and 2002, arthritis accounted for 9% of the overall increase in health care spending 
among Medicare beneficiaries (ranked fourth of 10 chronic conditions) (14). Spending for 
arthritis will undoubtedly increase substantially with the increasing number of baby boomers 
eligible for Medicare and the increasing number of expensive (but effective) total joint 
replacements (15). According to Rula et al (16), using effective health promotion and 
chronic disease management programs aimed at reducing the risk of onset and progression 
of chronic disease such as arthritis could save Medicare between $650 billion and $1.43 
trillion over 10 years.
Approximately half of adults with arthritis will be of traditional working age through 2040, 
which may affect the ability, type, and amount of work that they can do (4). Given the aging 
workforce, employers may need to increase efforts to modify worksites, job tasks, 
environments, and processes to accommodate employees who have arthritis. Vocational 
rehabilitation programs can result in the successful return to work of up to 69% of patients 
with rheumatic disease (17). Worksites might be useful places at which to offer physical 
activity and self-management education interventions that have been proven to improve pain, 
function, and quality of life in adults with arthritis (18).
What can be done to mitigate these projected effects? For individuals with arthritis, physical 
activity has been shown to decrease pain and improve function, which is particularly relevant 
for the millions of people with arthritis-attributable activity limitation (19). Walking 5,000–
7,499 steps per day has a protective effect (relative risk 0.50, 95% confidence interval 0.33–
0.76) against incident functional limitation (measured as slow gait speed) among adults with 
knee osteoarthritis (20). Walking programs such as the Arthritis Foundation’s Walk With 
Ease program have been proven to improve function, gait speed, strength, balance, and self-
efficacy and to reduce pain, fatigue, and stiffness; these programs are easy and inexpensive 
strategies for increasing physical activity, which in turn may reduce functional limitation 
(21).
Can the health care system accommodate these projected increases? By 2025, the expected 
demand for rheumatologists is expected to exceed supply by 2,576 adult and 33 pediatric 
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rheumatologists (22). The shortage of rheumatologists in non-urban areas is especially 
critical; for some areas, the closest rheumatologist is located >200 miles away (23). 
Shortages in the workforce of orthopedic surgeons, particularly among those performing 
total joint replacements, are also expected. Using sophisticated regression modeling 
accounting for growth in the population (not specifically growth in arthritis prevalence), rate 
of change in the number of arthroplasties from 1993 to 2010, age, race, sex, and Census 
region, Kurtz et al projected that the demand for total knee replacements will be 1.4 million 
per year by 2020 (15). Assuming that clinicians retire at age 65 years, the workforce of 
orthopedic surgeons in 2016 will be able to perform only 422,225 primary total knee 
replacements annually (24). Because the number of retiring surgeons will likely exceed the 
number of orthopedic residency slots in upcoming years, demand will outpace supply unless 
strategies for increasing the number of graduates of orthopedic training programs are 
immediately implemented (24). Strategies to address these shortages include using more 
physician assistants and nurse practitioners (25,26), implementing nurse-led clinics (27,28), 
and intensifying efforts to recruit trainees to the rheumatology and orthopedic specialties 
(29). As an adjunct to clinical care, health care providers can also refer patients to effective 
self-management education and physical activity programs offered in their local 
communities.
This study has several limitations. First, we could not take into account the effects of the 
current obesity epidemic, because census population projections do not include projections 
for body mass index (10). Obesity is a strong risk factor for knee osteoarthritis (30), which is 
one of the most common types of arthritis, and possibly other types of arthritis. If obesity 
could be taken into account, these estimates would likely be much higher, although we 
cannot speculate on the magnitude with any confidence at this time. Second, our analysis 
assumes that the 2010–2012 age- and sex-specific prevalence proportions will persist 
unchanged in the future, which may not be true, especially if the effects of the obesity 
epidemic affect later proportions. Last, public-access census projections were not available 
for race and ethnicity according to our age and sex stratifications; therefore, we were unable 
to assess the effects of the changing race and ethnicity demographics occurring through 
2040 (10).
The strengths of this study include use of the large population-based NHIS to calculate the 
baseline prevalence and use of a 3-year rolling average to smooth any year-to-year variations 
in prevalence. Our case-finding question includes arthritis and other rheumatic conditions 
that would typically be seen by rheumatologists (e.g., fibromyalgia) and has been shown to 
be valid for public health surveillance purposes (9). These projections are also useful in 
planning for future clinical and public health needs, assessing health care utilization, 
anticipating workforce demands, and informing health policy.
These projected increases in the prevalence of arthritis and arthritis-attributable activity 
limitation have serious implications for a condition that is already the most common cause 
of disability (2). This large and increasing burden of arthritis over the next 25 years, along 
with the important role that arthritis already plays in the millions of adults with multiple 
chronic conditions (31), suggest that arthritis will remain an important factor for personal 
health and quality of life as well as public health.
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Figure 1. 
Projected proportion of US adults with arthritis, according to age group and year.
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